NeuroPace, Inc.
$15.96
The Read: NeuroPace’s stock rose steadily after Q4 2025 guidance highlighted 20%+ RNS growth, stronger margins, and new AI tools, but then fell about 18% after a strong Q1 2026 beat due to a sharp sell-the-news reaction amid overbought conditions.
Price
Overlays
Panel
NPCE
Hover to view data
No Data